Spots Global Cancer Trial Database for net
Every month we try and update this database with for net cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Development and Validation of an Online Neurobehavioral Evaluation Tool for PTEN Patients | NCT05671107 | PTEN Hamartoma ... | NET | 3 Years - 45 Years | John Carroll University | |
| Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma | NCT00780663 | Neuroendocrine ... Carcinoid Tumor | Quarfloxin | 18 Years - | Cylene Pharmaceuticals | |
| Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients | NCT02075606 | NeuroEndocrine ... | lanreotide acet... | 18 Years - | Ipsen | |
| PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours | NCT05053854 | Neuroendocrine ... | Talazoparib | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET. | NCT04276597 | Pulmonary Neuro... Pheochromocytom... Paraganglioma Thymus Carcinoi... Unknown Primary... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... | 177Lu-DOTATOC | 18 Years - | Excel Diagnostics and Nuclear Oncology Center | |
| Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease | NCT01864070 | Liver Cancer | TheraSphere Everolimus Phone Call | 18 Years - | M.D. Anderson Cancer Center | |
| Registry on NEN Patients and COVID-19 | NCT04444401 | Neuroendocrine ... COVID-19 | 18 Years - | European Institute of Oncology | ||
| Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) | NCT01524783 | Advanced NET of... Advanced NET of... Neuroendocrine ... | Everolimus Placebo Best suportive ... | 18 Years - | Novartis | |
| Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma | NCT00780663 | Neuroendocrine ... Carcinoid Tumor | Quarfloxin | 18 Years - | Cylene Pharmaceuticals | |
| A Study of XmAb®18087 in Subjects With NET and GIST | NCT03411915 | Neuroendocrine ... Gastrointestina... | XmAb18087 | 12 Years - | Xencor, Inc. | |
| An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome | NCT00774930 | Carcinoid Syndr... | Lanreotide Placebo | 18 Years - | Ipsen | |
| Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors | NCT02586844 | Neuroendocrine ... Pancreatic Neur... | 18 Years - | University Health Network, Toronto | ||
| Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors | NCT02586844 | Neuroendocrine ... Pancreatic Neur... | 18 Years - | University Health Network, Toronto | ||
| Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour | NCT00842348 | Non Functioning... | lanreotide (Aut... | 18 Years - | Ipsen | |
| Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors | NCT01967537 | Neuroendocrine ... Von Hippel-Lind... Hippel-Lindau D... | 68Gallium DOTAT... Radio-guided su... | 10 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation | NCT04140409 | Neuroendocrine ... Carcinoid Syndr... | Sandostatin | 18 Years - | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | |
| Registry on NEN Patients and COVID-19 | NCT04444401 | Neuroendocrine ... COVID-19 | 18 Years - | European Institute of Oncology | ||
| A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations | NCT05199584 | Solid Tumors Wi... | ENV-101 (talade... | 18 Years - | Endeavor Biomedicines, Inc. | |
| Bone Metastases in neurOendocrine NEoplasms: naTural History, Prognostic Impact and Therapeutic Approach (MONET) | NCT04720391 | Bone Metastases Neuroendocrine ... | - | European Institute of Oncology | ||
| Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease | NCT01864070 | Liver Cancer | TheraSphere Everolimus Phone Call | 18 Years - | M.D. Anderson Cancer Center | |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | NCT05997056 | Neuroendocrine ... NET Pancreatic Neur... Gastrointestina... Pulmonary Neuro... | nab-sirolimus | 18 Years - | Aadi Bioscience, Inc. | |
| Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET. | NCT04276597 | Pulmonary Neuro... Pheochromocytom... Paraganglioma Thymus Carcinoi... Unknown Primary... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... | 177Lu-DOTATOC | 18 Years - | Excel Diagnostics and Nuclear Oncology Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
